GLP-3 (Retatrutide) is studied to better understand how three separate metabolic receptor pathways, GLP-1, GIP, and glucagon, interact to influence energy metabolism, fat signaling, and blood sugar regulation.

Retatrutide represents the next step in multi-receptor incretin pharmacology research, building on the dual-agonist framework established by GLP-1/GIP compounds by incorporating glucagon receptor engagement as an additional signaling pathway. While GLP-1R and GIPR activation drives insulin secretion and incretin signaling in pancreatic cell models, GCGR engagement introduces a complementary layer — one associated with hepatic glucose output regulation, thermogenic signaling, and energy expenditure pathway activity in preclinical metabolic models.

It is worth noting a nomenclature distinction relevant to researchers: GLP-3 as a naturally occurring peptide is a biochemically distinct product of proglucagon processing in intestinal L-cells, with negligible activity at GLP-1R and GLP-2R in cell-based assays. Retatrutide, marketed under the GLP-3 designation in some research contexts, is a synthetic triple agonist compound — pharmacologically unrelated to the endogenous GLP-3 peptide family. This distinction is important when designing receptor selectivity or structure-activity studies.

All product supplied here is intended exclusively for controlled laboratory settings and is not formulated for human or veterinary administration.

• CAS Number: 2381089-83-2
• Molecular Weight: ~4731 g/mol
• Purity: ≥99%
• Also Known As: Retatrutide, LY3437943 (development code), GLP-1/GIP/Glucagon triple agonist, Triple incretin receptor agonist
• Chemical Formula: C₂₂₁H₃₄₂N₄₆O₆₈

In cell-based and preclinical models, Retatrutide engages three receptor targets through distinct but complementary signaling pathways. At GLP-1R, it activates Gs-coupled cAMP signaling in pancreatic beta-cell preparations, contributing to glucose-dependent insulin secretion and glucagonostatic activity. At GIPR, it mimics native GIP signaling to drive complementary insulinotropic responses and adipokine modulation in adipocyte preparations — consistent with the dual incretin mechanisms characterized in GLP-1/GIP research models.

The third receptor arm — GCGR engagement — is what distinguishes Retatrutide’s signaling profile from dual incretin agonists. Glucagon receptor activation in hepatic and adipose cell preparations has been associated with increased cAMP-driven energy expenditure signaling, fatty acid oxidation pathway activity, and thermogenic marker upregulation. In the context of triple receptor co-activation, this glucagon-mediated energy expenditure signal operates alongside the insulin-promoting incretin pathways — a combination studied for its net effect on metabolic signaling balance in preclinical models.

Together, the three receptor pathways produce a layered signaling profile that makes Retatrutide a distinctive tool compound for studying multi-receptor metabolic crosstalk in controlled experimental frameworks.

• Triple Receptor Agonism Research
• Incretin Pathway Crosstalk Studies
• Energy Expenditure Signaling
• Metabolic Receptor Pharmacology
• Adipokine and Lipid Metabolism Research
• Glucagonostatic and Hepatic SignalinG
• Multi-Receptor Agonist Modeling